Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — December 2023

Genmab — December 2023

Planlagt Fastgjort Låst Flyttet Genmab
860 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    ProinvestorNEWS
    wrote on sidst redigeret af
    #98

    Genmab hæves til "køb" hos schweizisk storbank https://www.proinvestor.com/investornyt/1086822/genmab-haeves-til-kob-hos-schweizisk-storbank

    1 Reply Last reply
    0
    • K Offline
      K Offline
      Klarussen
      wrote on sidst redigeret af
      #99

      På tide

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #100

        Sounds promissing, “ encouraging early clinical activity, including complete responses”.

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #101

          Plural CRs in heavy treated pts. Very interesting !

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #102

            agree, very early ofcourse, but the news we are getting so far seems promising !

            1 Reply Last reply
            0
            • L Offline
              L Offline
              lahn1
              wrote on sidst redigeret af
              #103

              Doesn't this support our thinking yesterday, that the expansion of trial pts. is a possitiv sign ?

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #104

                I would think so, yes. Let's hope we'll get some comments on it next week.

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #105

                  "OX40 has been implicated in the pathologic cytokine storm associated with certain viral infections, including the H5N1 bird flu" If it doesn't work in solid tumors ; Biontech knows how to create vaccins 😉 https://en.wikipedia.org/wiki/CD134

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #106

                    I find it comforting that BioNTech is willing to try the second Hexabody. After all, the technology has not yet been proven. But it would not surprise me if they have also seen the data on Hexabody-DR5/DR5 . Doubt they are allowed to see Hexabody-CD38 data early though.

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #107

                      Genmab har ændret gen1046 til acasunlimab på deres hjemmeside, men har (endnu) ikke ændret gen1042. Så vi mangler den endelige beslutning.

                      1 Reply Last reply
                      0
                      • T Offline
                        T Offline
                        Teller
                        wrote on sidst redigeret af
                        #108

                        Det ser da lovende ud, mon KYSO moment er i sigte? 🙂

                        1 Reply Last reply
                        0
                        • K Offline
                          K Offline
                          Klarussen
                          wrote on sidst redigeret af
                          #109

                          Hvor er det smukt (Genmab IR): "We have committed to a new vision for our future that by 2030, our knock-your-socks-off KYSO antibody medicinesTM are fundamentally transforming the lives of people with cancer and other serious diseases."

                          1 Reply Last reply
                          0
                          • FrittenF Offline
                            FrittenF Offline
                            Fritten
                            wrote on sidst redigeret af
                            #110

                            Spændende artikel om 5 store ting på ASH, hvor de nævner Genmab som 1 af dem:

                            1 Reply Last reply
                            0
                            • FrittenF Offline
                              FrittenF Offline
                              Fritten
                              wrote on sidst redigeret af
                              #111

                              https://firstwordpharma.com/story/5807409?from=article

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                ProinvestorNEWS
                                wrote on sidst redigeret af
                                #112

                                Johnson & Johnson’s prescription for growthhttps://www.proinvestor.com/investornyt/1087102/johnson-amp-johnsonrsquos-prescription-for-growth

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  ProinvestorNEWS
                                  wrote on sidst redigeret af
                                  #113

                                  "Key pharmaceuticals like Darzalex, Carvykti, and Stelara are pivotal revenue drivers, illustrating J&J's steadfast commitment to developing and delivering life-altering treatments. These flagship drugs continue to showcase robust market demand, underpinning the company's revenue expectations"
                                  .

                                  1 Reply Last reply
                                  0
                                  • T Offline
                                    T Offline
                                    Teller
                                    wrote on sidst redigeret af
                                    #114

                                    God formiddag 🙂

                                    1 Reply Last reply
                                    0
                                    • H Offline
                                      H Offline
                                      Hen
                                      wrote on sidst redigeret af
                                      #115

                                      😉

                                      1 Reply Last reply
                                      0
                                      • K Offline
                                        K Offline
                                        Klarussen
                                        wrote on sidst redigeret af
                                        #116

                                        @The Note: siden det er dig, så går det nok 😄

                                        1 Reply Last reply
                                        0
                                        • K Offline
                                          K Offline
                                          Klarussen
                                          wrote on sidst redigeret af
                                          #117

                                          Fint gap

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper